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a  b  s  t  r  a  c  t
The  authors  present  the  guidelines  of the French  Oto-rhino-laryngology  – Head  and  Neck  Surgery Society
(SFORL)  regarding  pain  management  in children  and adults  following  tonsillectomy.  A  multidisciplinary
work  group  was  entrusted  with a literature  review.  Guidelines  were  drawn  up based  on  the  articles
retrieved  and  the  group  members’  experience.  They  were  read  over  by  an  editorial  group  indepen-
dent  of  the  work  group.  A  coordination  meeting  drew  up  the ﬁnal  version.  Guidelines  were  graded




anti-inﬂammatory  drugs  (NSAIDs)  are  recommended  in association  with  paracetamol  in elevated  respi-
ratory risk  and  especially  obstructive  sleep  apnea  syndrome;  in elevated  hemorrhagic  risk  (hemostasis
disorder,  surgical  problems,  etc.),  tramadol  is recommended.  Two  other  treatment  schedules  (modiﬁed
NSAIDs  and  corticosteroids)  have  not  undergone  dedicated  study  and  should  be assessed.  Management
of  post-tonsillectomy  pain  in children  is  founded  on  individual  risk/beneﬁt  analysis.
© 2014  Published  by Elsevier  Masson  SAS.. Introduction
Tonsillectomy is one of the most frequent procedures in chil-
ren. It is associated with moderate to severe postoperative pain of
ome 7 days’ evolution [1] (level of evidence 2). Several points are
o be taken into account in the decision tree for post-tonsillectomy
nalgesia:
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879-7296/© 2014 Published by Elsevier Masson SAS.• post-tonsillectomy pain is mainly of inﬂammatory origin, with a
background component exacerbated by mechanical stimulation
such as swallowing, feeding and vomiting;
• the pediatric tonsillectomy population is presently relatively
young, frequently presenting obstructive syndrome in periods of
muscular relaxation (sleep or sedation), with risk of obstructive
apnea potentially inducing hypoxic episodes (obstructive sleep
apnea syndrome: OSAS). This population has been shown to be
particularly sensitive to the respiratory depression effects of post-
operative morphine [2] (level of evidence 2). Obese children are
also at high risk of post-tonsillectomy respiratory complications
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is associated with high levels of postoperative pain [4] (level of
evidence 2);
apart from during the ﬁrst few immediate postoperative hours,
pain is managed at home by the parents. This management
without direct medical supervision requires not only educa-
tional documents to be provided to the parents but also the use
of substances having a long and predictable therapeutic inter-
val. Ideally, the analgesics should display satisfactory efﬁcacy
adapted to the type of pain at well-deﬁned normal-for-weight
doses (low intersubject variability), with few if any severe or
life-threatening side effects (respiratory depression or bleeding);
home analgesia often proves inadequate, despite correct medical
prescription [5] (level of evidence 2). During the ﬁrst 3 postopera-
tive days, non-conditional scheduled administration is associated
with higher intake than administration on demand, with lower
pain scores [6] (level of evidence 2);
the principle of multimodal pain management is especially
important here, as associating substances with additive or,
preferably, synergic effects can optimize the risk/beneﬁt ratio [7]
(level of evidence 1);
side effects in the form of postoperative nausea and vomi-
ting (PONV) are frequent after tonsillectomy. Mechanically, they
aggravate pain and increase the risk of bleeding. Treatment
and prevention of PONV is thus an integral part of pain man-
agement, especially as some analgesic molecules (non-steroidal
anti-inﬂammatories (NSAIDs), corticosteroids, etc.) display anti-
emetic effects and others (morphine, tramadol, etc.) emetic
effects.
The post-tonsillectomy course thus involves a complex triad of
ain–vomiting–bleeding, managed by optimizing the compromise
round a principal target that may  vary according to the prescriber’s
hoice in terms of type and level of risk. As well as this triad, there
s a risk of respiratory depression when opioids or opioid deriva-
ives are used in analgesia, especially in children with elevated
ensitivity to respiratory depression effects (OSAS).
. Exclusion of codeine
Until it was excluded from the pediatric market, codeine used
o be the step-2 analgesic most commonly prescribed for post-
onsillectomy pain.
Codeine is a prodrug metabolized into inactive metabolites
80%) and morphine (20%), the active metabolite underlying its
nalgesic action. Morphine formation depends on cytochrome
YP2D6, which is highly variable due to its genetic polymor-
hism and frequency of duplication. Thus, the metabolism (and
ence analgesic effect) of codeine varies greatly according to geno-
ype: in low metabolizers (5–10% of caucasians), efﬁcacy is low
r absent, while in ultrarapid metabolizers (2% of caucasians, but
20% in Africa and the Middle East) large or very large amounts
f morphine are formed, with risk of overdose and respiratory
epression. A certain number of such accidents have been reported,
specially in children undergoing tonsillectomy, receiving postop-
rative codeine at home.
In 2012, the FDA reviewed the data for adverse events between
969 and May  2012 and found 13 cases of codeine-related death
n = 10) or severe respiratory depression (n = 3), 7 of which had been
escribed in the literature [8–11] (level of evidence 4). Ages ranged
rom 21 months to 9 years. Most cases (11/13) were secondary
o tonsillectomy (n = 8) or upper-airway infection (n = 3). In most
ases, the codeine doses met  US guidelines: around 1 mg/kg every
–6 hours. In 7 children, genetic analysis had determined the level
f CYP2D6 metabolic activity: 3 were ultrarapid metabolizers, 3
ormal and 1 a probable ultrarapid metabolizer. Two  other casesgy, Head and Neck diseases 131 (2014) 233–238
of death following tonsillectomy (3 and 12 years) were identiﬁed
in a survey by the American Academy of Otolaryngology – Head
and Neck Surgery, both in children diagnosed as ultrarapid metab-
olizers [12] (level of evidence 4). These post-tonsillectomy deaths
were systematically associated with preoperative OSAS.
In February 2013, the FDA therefore contraindicated postopera-
tive codeine in tonsillectomy in the USA, recommending its use in
child analgesia only if beneﬁt appears to outweigh risk [13] (level
of evidence 1).
In Europe, the European Medicines Agency (EMA) takes the
same attitude, publishing a communiqué by the PRAC (Pharma-
covigilance Risk Assessment Committee), which was  immediately
adopted by the French national drug safety agency, ANSM (Agence
Nationale de Sécurité du Médicament, formerly known as AFSSAPS)
on April 12, 2013, restricting the market authorization for codeine
[14] (level of evidence 1), which is no longer recommended in chil-
dren following tonsillectomy or adenoidectomy.
3. Risk/beneﬁt ratio for NSAIDs
NSAIDs provide more effective pain relief than paracetamol
or placebo, with reduced PONV [15] (level of evidence 1). In
post-tonsillectomy care, associated paracetamol-NSAID is more
effective than either in isolation [16] (level of evidence 1). NSAIDs
(ibuprofen) provide similar analgesic effects to associated codeine-
paracetamol, with less impact on vomiting [17] (level of evidence
2).
Their main drawback lies in interference with coagulation
(impaired primary hemostasis due to thromboxane A2 inhibi-
tion), aggravating, at least in theory, the risk of post-tonsillectomy
hemorrhagic complications; in the literature, the rate of such hem-
orrhage is around 3%, with onset within the ﬁrst 24 hours (primary
hemorrhage) or 5–10 days (secondary hemorrhage) [18] (level of
evidence 1). There is abundant literature on the possible elevated
risk of hemorrhage with NSAIDs, but conclusions presently remain
unclear: the low rate of post-tonsillectomy hemorrhagic complica-
tions makes for statistically underpowered studies. A meta-analysis
approach should compensate for the low power of the individual
studies, but the numerous meta-analyses that have been published
are weakened by the multiplicity of drugs and doses and varying
assessment criteria (intraoperative bleeding, postoperative bleed-
ing, readmission, revision surgery, etc.).
In 2003, Moiniche’s literature review (meta-analysis of 25 stud-
ies, with 970 patients receiving NSAIDs) found NSAIDs to show
analgesic impact equivalent to that of opioids, with lower risk of
PONV but a higher risk of revision surgery for bleeding, although
not of other bleeding-related factors [19] (level of evidence 1). Mar-
ret’s meta-analysis, published the same year, and based on 7 of the
studies included in the previous review, found increased risk of
revision surgery for bleeding and advised against the use of NSAIDs
following tonsillectomy [20] (level of evidence 1).
A third meta-analysis, published in 2003, including adult and
pediatric studies, reported increased risk of bleeding with postop-
erative aspirin, but not with other NSAIDs [21] (level of evidence
1).
In 2005, Cardwell analyzed 15 pediatric studies (1046 chil-
dren undergoing tonsillectomy) in a meta-analysis based on the
Cochrane collaboration. NSAIDs were not associated with higher
rates of bleeding, requiring surgical revision or not, than opioids or
placebo, but did show lower risk of PONV. The authors concluded
that NSAIDs were not contraindicated following tonsillectomy,
while highlighting the lack of power of the underlying studies [22]
(level of evidence 1).
This analysis of the Cochrane database was  updated in 2010,
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nalyzed. Overall, the authors found the data to be insufﬁcient to
ule out elevated risk of hemorrhage with use of NSAIDs following
onsillectomy [23] (level of evidence 1).
A large American retrospective study of 1160 children, 467 of
hom had received ibuprofen (5 mg/kg/6 h) following tonsillec-
omy, found no signiﬁcant difference in postoperative bleeding
s compared with analgesia based on codeine and paracetamol
acetaminophen, in the North American terminology) [24] (level
f evidence 4).
In 2013, a Canadian meta-analysis assessed the incidence of
ostoperative bleeding in 36 studies, totaling 1747 children and
446 adults, receiving either NSAIDs, placebo or opioids follow-
ng tonsillectomy. Bleeding rates were not higher with NSAIDs,
ncluding in children (18 studies). Focusing on pediatric studies
ith ibuprofen (4 studies, 535 children), there was  again no sig-
iﬁcant impact on bleeding. The authors concluded that NSAIDs
an be considered reliable analgesics in tonsillectomy [25] (level of
vidence 1).
Likewise, the recently published American tonsillectomy
uidelines clearly state that ibuprofen can be “safely” used post-
peratively [26] (level of evidence 1).
It is noteworthy that there is no argument in the literature
ndicating elevated infection risk related to NSAIDs (ibuprofen) in
onsillectomy.
In all, the risk/beneﬁt ratio for NSAIDs, and particularly for
ibuprofen, seems favorable, although a slight risk of greater
post-tonsillectomy bleeding cannot be ruled out.
. Risk/beneﬁt ratio for dexamethasone
Dexamethasone is a corticosteroid; intraoperative intravenous
iv) injection is associated with reduced PONV and postop-
rative pain and earlier resumption of feeding [27] (level of
vidence 1). Intraoperative injection (0.15 mg/kg) is currently rec-
mmended in tonsillectomy in France [28,29] (level of evidence
).
There are, however, doubts regarding interference with post-
onsillectomy hemostasis, raised by a pediatric study published
n 2008. The authors conﬁrmed the dose-dependent anti-emetic
ction of intraoperative dexamethasone, but reported increased
ostoperative bleeding that was signiﬁcant at doses of 0.05 mg/kg
nd 0.5 mg/kg [30] (level of evidence 1). They concluded that
examethasone should be avoided in children undergoing tonsil-
ectomy. It is noteworthy that in this study children were given
escue doses of ibuprofen, resort to which was  reduced by intra-
perative administration of dexamethasone; the impact of the
ssociation of the two was not assessed as the study was termi-
ated before the end of inclusion due to the merely moderate
esults.
Geva’s 2011 meta-analysis included 14 studies using intraop-
rative dexamethasone at doses ranging from 0.05 to 8 mg/kg; no
ncrease in bleeding was found [31] (level of evidence 1).
In 2012, a multicenter prospective randomized study in chil-
ren, comparing intraoperative dexamethasone bolus (0.5 mg/kg)
ersus placebo, found no objective increase in bleeding but could
ot rule out increased bleeding on subjective assessment [32] (level
f evidence 1).In 2012, Shargorodsky’s meta-analysis included 12 pediatric
tudies, comparing intraoperative dexamethasone versus placebo,
ound no signiﬁcant overall association with postoperative bleed-
ng; the results, however, did not rule out increased risk ofgy, Head and Neck diseases 131 (2014) 233–238 235
postoperative bleeding with certain doses of dexamethasone,
notably between 0.4 and 0.6 mg/kg [33] (level of evidence 1).
Also in 2012, Plante’s meta-analysis of 29 randomized controlled
studies, including 2674 patients, found no increased bleeding, but
an increased rate of revision surgery for severe bleeding with
dexamethasone. The authors found increased bleeding in case of
associated postoperative NSAIDs [34] (level of evidence 1).
Overall, intraoperative dexamethasone was recommended
in France in two expert conferences on tonsillectomy [28,29]
(level of evidence 1) and in good practice guidelines for pedi-
atric pain [7] (level of evidence 1). There remains doubt as to
the impact on postoperative bleeding, but a dose of 0.15 mg/kg
seems not to be implicated.
Interaction between NSAIDs and dexamethasone has not
been studied in terms of hemorrhagic risk, but the association
may  legitimately be suspected given the above ﬁndings for
each.
5. Risk/beneﬁt ratio for oral corticosteroids
Postoperative oral corticosteroids (for 3 to 7 days) are some-
times considered for their anti-inﬂammatory and anti-emetic
action, but have been little assessed in this indication. Palme, in
a low-powered study, compared prednisolone versus placebo for
7 days after tonsillectomy; he reported a limited effect of pred-
nisolone on nausea, vomiting and pain score [35] (level of evidence
2). In 2012, Macassey showed that prednisolone, compared to
placebo, as adjuvant to standard analgesia (paracetamol, codeine,
ibuprofen) did not affect pain proﬁle or vomiting in children fol-
lowing tonsillectomy [36] (level of evidence 2).
Overall, the risk/beneﬁt ratio for oral corticosteroids has not
been assessed. Theoretically, they could be useful postopera-
tively given their pain-relieving anti-inﬂammatory effect and
the absence of any risk of respiratory depression. The strategy,
however, needs prospective assessment, especially in terms of
analgesic efﬁcacy and risk of secondary bleeding and infection.
6. Risk/beneﬁt ratio for tramadol
Tramadol is a step-2 analgesic with two-fold action mechanism.
It is ﬁrstly a  opioid receptor agonist with relatively low afﬁnity
(1000 to 2000 times weaker than morphine) [37]. It also acts as a
serotonin and noradrenalin reuptake inhibitor.
The clinical efﬁcacy of iv tramadol in the early postoperative
course has been demonstrated. In children undergoing tonsillec-
tomy, iv tramadol at 1–2 mg/kg at induction seems to provide
pain relief comparable to morphine (0.1 mg/kg iv), with less PONV
[38] (level of evidence 2). In children with OSAS, intraoperative iv
tramadol (2 mg/kg) provides pain relief comparable to morphine
(0.1 mg/kg) with fewer desaturation episodes in the second post-
operative hour [39] (level of evidence 2). Oral tramadol shows good
bioavailability: 1.5 mg/kg administered in drops shows peak con-
centration by 30 min, with an analgesic effect lasting 6 hours [40].Tramadol administered intraoperatively (3 mg/kg, iv) then post-
operatively (2.5 mg/kg, per os) provides better quality analgesia
for the ﬁrst 3 postoperative days than paracetamol [41] (level of
evidence 2).
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Table 1
Treatment schedules.








Recovery room morphine Recovery room morphine Recovery room morphine Recovery room morphine
Paracetamol, iv or per os
Ibuprofen in hospital
Paracetamol, iv or per os
Tramadol in hospital
Paracetamol, iv or per os Paracetamol, iv or per os
Ibuprofen in hospital
At  home Paracetamol per os Paracetamol per os Paracetamol per os Paracetamol per os
Ibuprofen Tramadol Prednisolone Ibuprofen
In hospital: postoperative analgesia systematically begins in the intraoperative period (or even the preoperative period, with premedication) with a morphine derivative and
dexamethasone, possibly associated in advance to paracetamol. Morphine derivatives are titrated in the recovery room, and paracetamol is continued. Oral route is initiated
in  hospital before discharge.
At home: paracetamol is administered systematically, at pre-scheduled times.
NSAID option: analgesia is based on ibuprofen, following a systematic predetermined schedule. Increased risk of hemorrhage cannot be formally excluded, and monitoring
and  parent education should take account of this. If analgesia proves insufﬁcient, rescue by tramadol may  be considered after medical consultation.
Modiﬁed NSAID option: this option is identical to the previous one, except that there is no intraoperative injection of dexamethasone. The rationale is to avoid a possible
increase in hemorrhage risk raised by both intraoperative dexamethasone and postoperative NSAIDs. To prevent PONV, dexamethasone may be replaced by ondansetron.
Tramadol option: analgesia is based on tramadol, following a systematic predetermined schedule. Signs of morphine-like overdose may occur (vomiting, sedation and
especially respiratory depression), and monitoring and parent education should take account of this. Preoperative OSAS requires sharpened vigilance and may  indicate that
NSAIDs  would be preferable. If analgesia proves insufﬁcient, rescue by ibuprofen may  be considered after medical consultation.
C lone), following a systematic predetermined schedule. This option has not been validated
i cy (analgesia) and risk (notably, hemorrhage). Home monitoring and parent education




































Overall, the risk/beneﬁt ratio for tramadol presently appears
favorable. Respiratory risk is considered low under standard
administration conditions (1 mg/kg every 6 h). Follow-up, how-
ever, is limited for pediatric applications, and no study has been
published on the impact of genetic polymorphism on the respi-
ratory effects of tramadol. As with codeine, there may be a
risk of adverse respiratory events in ultrarapid metabolizers
and/or subjects at high risk of obstructive apnea. Vigilance is
thus called for, and any events should be reported.orticosteroid option: analgesia is based on an oral corticosteroid (such as predniso
n  the literature and needs at least observational prospective assessment of efﬁca
hould take account of this. If analgesia proves insufﬁcient, rescue by tramadol may
Side effects are those of opioids, with nausea and vomiting and
espiratory depression being the main two complications in tonsil-
ectomy.
Nausea and vomiting are frequently associated with tramadol
at around 40% for iv and 10% per os), although incidence seems
ower than with morphine derivatives [38] (level of evidence 2).
Respiratory depression is possible, but theoretically rare. In
ain-free adults, 100 mg  oral tramadol reduces the CO2 respira-
ory threshold by 30%, without impairing wakefulness [42] (level
f evidence 2). Tramadol-induced respiratory depression is treated
y naloxone.
Finally, CYP2D6 enables O-demethylation of tramadol, produc-
ng an active metabolite, M1  (O-desmethyl tramadol: enantiomer
), with an afﬁnity for  receptors 5 to 100 greater than tramadol
37]. As with codeine, the genetic polymorphism of CYP2D6 leads
o variable levels of production of this metabolite and (as with
odeine) variation in analgesic efﬁcacy (reduced in slow metab-
lizers) and incidence of side effects such as respiratory depression
increased in ultrarapid metabolizers). These variations may  be less
han with codeine, given the double action mechanism of tramadol
nd the differential afﬁnities of the metabolites, O-desmethyl tra-
adol having 10-20 times less -receptor afﬁnity than morphine
37].
Some cases suggesting that tramadol may  be associated with
evere respiratory depression episodes have been reported. Such
pisodes have been described in intoxication for mean doses of
000 mg  in adults, but also at levels as low as 200 mg  [43] (level
f evidence 4). A case was reported of prolonged apnea in a
oung woman who had received 50 mg  immediate postopera-
ive iv tramadol [44] (level of evidence 4). A case of fatal apnea
as also reported in an obese patient [45] (level of evidence
). Finally, kidney failure induces M1  metabolite accumulation
nd may  cause respiratory depression [46] (level of evidence
).
A reported neonatal death may  have implicated tramadol
dministered postpartum to the mother, who was breast-feeding
47] (level of evidence 4).
A case of serotonergic intoxication was reported in an 8-month-
ld child who had accidentally ingested 200 mg  tramadol, resulting
n agitation and insomnia, without convulsions or respiratory
epression; symptoms resolved spontaneously [48] (level of evi-
ence 4).7. Risk/beneﬁt ratio for oral morphine
Morphine is still the analgesic of choice in severe pain. In
children, parenteral morphine reduces postoperative pain [49]
(level of evidence 1). Oral morphine has comparable analgesic
effects. In home management of post-tonsillectomy pain, given
that codeine is no longer available, oral morphine is an option
[50] (professional agreement). Parents then should be specially
trained in the monitoring and primary treatment of side effects.
Dosage should be systematically adapted to weight, using the low-
est effective dose. The most frequent side effects are nausea and
vomiting, sedation, pruritus and urinary retention [51] (level of
evidence 2). Respiratory depression is the most adverse side effect,
especially in young children, with onset at blood concentrations
exceeding 20 g/ml [52] at variable intervals after administra-
tion. There are at present no studies assessing the feasibility and
harmlessness of home administration of oral morphine following
tonsillectomy.
In all cases, children with OSAS are highly sensitive to mor-
phine, which should be used with great caution, especially in young
children or in case of comorbidity.
Finally, home administration of morphine by the parents entails
a non-negligible risk of error, especially as galenic formulation is
presently poor in France.
In terms of galenic formulation, drop-dosage involves a risk of
error in morphine and morphine derivatives. It has, for example,
been demonstrated that the mass of codeine per drop can vary by
a factor of 2 [10] (level of evidence 4).
I. Constant et al. / European Annals of Otorhinolaryngolo
Overall, the risk/beneﬁt ratio for oral morphine, given the
high sensitivity of young children with preoperative OSAS and







































[unfavorable in the context of post-tonsillectomy care.
. Reminders regarding paracetamol
Isolated post-tonsillectomy paracetamol generally provides
nsufﬁcient analgesia [53] (level of evidence 2). Associated to mor-
hine derivatives or NSAIDs, it has an additive or synergic effect
16,54] (level of evidence 1). Associated iv and, as early as possi-
le, oral paracetamol is recommended for post-tonsillectomy pain
7,28] (level of evidence 1).
In the light of the literature analysis, the work group recom-
mends (Table 1):
• in case of elevated respiratory risk (severe OSAS, comor-
bidity, etc.), an NSAID-based schedule is to be preferred,
avoiding risk of respiratory depression;
• in case of elevated hemorrhagic risk (hemostasis disorder,
surgical problems, etc.), a tramadol-based schedule is to be
preferred, avoiding increased hemorrhagic risk;
• the work group recommends assessing two other schedules
(modiﬁed NSAIDs, and corticosteroids) that have not been
the focus of speciﬁc study;
• the work group recommends repeat medical assessment in
case of insufﬁcient analgesia on the prescribed schedule.
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